FOGHORN THERAPEUTICS I

Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day

11 مارس 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

10 مارس 2022 06:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference

28 فبراير 2022 15:05:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Chief Scientific Officer Succession

10 يناير 2022 06:00:02 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

07 يناير 2022 15:05:00 بحسب Nasdaq GlobeNewswire

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform

13 ديسمبر 2021 05:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference

11 نوفمبر 2021 15:05:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

09 نوفمبر 2021 06:00:02 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit

19 أكتوبر 2021 15:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

01 سبتمبر 2021 15:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

23 أغسطس 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

10 أغسطس 2021 06:00:02 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

03 أغسطس 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

09 يوليو 2021 07:36:31 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th

08 يونيو 2021 06:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Present in Two Upcoming Investor Conferences

26 مايو 2021 07:00:03 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286

17 مايو 2021 06:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Corporate Update

11 مايو 2021 06:00:02 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Appoints Ian Smith to its Board of Directors

28 أبريل 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Corporate Update

18 مارس 2021 07:00:00 بحسب Nasdaq GlobeNewswire